TY - JOUR
T1 - NCAM Mimetic Peptides
T2 - Potential Therapeutic Target for Neurological Disorders
AU - Chu, Chengyan
AU - Gao, Yue
AU - Lan, Xiaoyan
AU - Thomas, Aline
AU - Li, Shen
N1 - Funding Information:
The work was fund by the National Natural Science Foundation of China (81300985), Natural Science Foundation of Liaoning Province (2015020549) and Dalian Municipal Health and Family Planning Project (1711014). The authors declare that they have no conflict of interest.
Funding Information:
Acknowledgements The work was fund by the National Natural Science Foundation of China (81300985), Natural Science Foundation of
Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - The neural cell adhesion molecule (NCAM) plays a pivotal role in the development and maintenance of the nervous system via homophilic (NCAM–NCAM) and heterophilic (NCAM-other molecules) interactions. Many synthetic peptides have been engineered to mimic these interactions and induce NCAM-downstream signaling pathways. Such NCAM mimetics have displayed neuritogenic and neuroprotective properties, as well as synaptic modulation in vitro and in vivo. Furthermore, they have been used successfully in preclinical studies to treat neurological disorders including stroke, traumatic brain injury and Alzheimer’s disease. This review focuses on recent progress in the development of NCAM mimetic peptides, in particular, on establishing C3, plannexin, and FGL as therapeutic candidates for neurological disorders.
AB - The neural cell adhesion molecule (NCAM) plays a pivotal role in the development and maintenance of the nervous system via homophilic (NCAM–NCAM) and heterophilic (NCAM-other molecules) interactions. Many synthetic peptides have been engineered to mimic these interactions and induce NCAM-downstream signaling pathways. Such NCAM mimetics have displayed neuritogenic and neuroprotective properties, as well as synaptic modulation in vitro and in vivo. Furthermore, they have been used successfully in preclinical studies to treat neurological disorders including stroke, traumatic brain injury and Alzheimer’s disease. This review focuses on recent progress in the development of NCAM mimetic peptides, in particular, on establishing C3, plannexin, and FGL as therapeutic candidates for neurological disorders.
KW - Bioactive peptides
KW - Fibroblast growth factor receptor
KW - Mimetic peptides
KW - Neural cell adhesion molecule
KW - Neurological disorders
UR - http://www.scopus.com/inward/record.url?scp=85049770767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049770767&partnerID=8YFLogxK
U2 - 10.1007/s11064-018-2594-8
DO - 10.1007/s11064-018-2594-8
M3 - Review article
C2 - 30003388
AN - SCOPUS:85049770767
SN - 0364-3190
VL - 43
SP - 1714
EP - 1722
JO - Neurochemical Research
JF - Neurochemical Research
IS - 9
ER -